Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection

NCT03820258 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Stopped SOF/VEL/VOX will not be evaluated in younger age groups.

Conditions

Hepatitis C Virus Infection

Interventions

DRUG: SOF/VEL/VOX

Sponsor

Gilead Sciences